Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,600 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Skin Patch Clear all

Conditions: Cervical Dysplasia
Interventions: Nicotine Replacement Therapy, Electronic Cigarettes; Other · Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Smoking Cessation, Harm Reduction
Interventions: Nicoderm, Nicorette 4Mg Chewing Gum, Nicorette Lozenge Product, BIDI e-cigarette, on!; Drug · Other
Lead sponsor: Rose Research Center, LLC; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Back Pain Lower Back Chronic
Interventions: Buprenorphine transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 84
States / cities: Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 71 more

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: Nicotine patch, MK-4334, Placebo patch, Placebo capsule; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Actinic Keratosis
Interventions: Biopsy, Calcipotriene, Fluorouracil; Procedure · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Tucson, Arizona • Boston, Massachusetts • St Louis, Missouri + 1 more

Conditions: Postoperative Pain After Breast Reconstruction With Abdominal Flap
Interventions: Fentanyl, Inactive patch; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nicotine Dependence
Interventions: Sustained Care, Usual Care; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Melanoma and Other Malignant Neoplasms of Skin, Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma of the Skin
Interventions: Skin lesion diagnostic device evaluation; Device
Lead sponsor: VeriSkin, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Pleasanton, California • Walnut Creek, California • Tampa, Florida + 3 more

Conditions: Osteoarthritis, Knee
Interventions: Lidoderm, Placebo patch; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 24
States / cities: Birmingham, Alabama • Hueytown, Alabama • Tallassee, Alabama + 21 more

Conditions: Amblyopia
Interventions: Atropine, Eye Patch; Drug · Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Amblyopia
Interventions: Eye patch, Spectacles; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 3 Years to 7 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Fullerton, California • Durham, North Carolina

Conditions: Restless Legs Syndrome, End-Stage Renal Disease
Interventions: Rotigotine, Placebo; Drug
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Brandon, Florida • Newton, Massachusetts • West Seneca, New York + 3 more

Conditions: Female Sexual Dysfunction
Interventions: Electrical Stimulation, Smart vibrator; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Stress Urinary Incontinence
Interventions: Testosterone patch, Placebo; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: Zucapsaicin, Placebo patch; Drug
Lead sponsor: Winston Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Port Chester, New York

Conditions: Smoking, Smoking Cessation, Adherence, Nicotine Dependence, Motivation
Interventions: Short Term Combination Nicotine Replacement Therapy (patch + gum), Long Term Combination Nicotine Replacement Therapy (patch + gum), Intensive Maintenance Counseling, Cognitive Medication Adherence Counseling (CAM), Electronic Medication Monitoring Device (the Helping Hand) + Feedback, Automated Adherence Prompting Phone Calls; Drug · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alopecia Areata
Interventions: Intralesional Triamcinolone 2.5 mg/ml, Intralesional Triamcinolone 5 mg/ml, Intralesional Triamcinolone 10 mg/ml, Intralesional Saline; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Tattoo; Pigmentation, Melasma, Benign Pigmented Lesion
Interventions: PicoPlus laser system; Device
Lead sponsor: CynosureLutronic; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Newport Beach, California • Elmhurst, New York • New York, New York + 1 more

Conditions: Allergic Conjunctivitis
Interventions: Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2%, Artificial tears; Drug
Lead sponsor: Senju USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Skin Cancer
Interventions: OIR Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Low Back Pain
Interventions: Bupivacaine TTS (Bupivacaine Patch), Placebo patch; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Tempe, Arizona • La Mesa, California • Torrance, California + 18 more

Conditions: Photoallergy
Interventions: SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519), Sodium chloride [NaCl]; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Pinellas Park, Florida

Conditions: Comedogenicity
Interventions: Lotion, Negative Control; Device · Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Vital Signs
Interventions: VSP System - NEHB Configuration, VSP System - PAL Configuration; Device
Lead sponsor: LifeWatch Services, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Smoking Cessation in Women With Gynecological Conditions

Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction

Smoking Cessation Following Psychiatric Hospitalization

TruScore Standalone Clinical Study

Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

At-Home Neuromodulation for Female Sexual Dysfunction

Testosterone Replacement in Postmenopausal Women With Stress Urinary Incontinence

Civamide Patch Safety, Tolerability and PK Study

Evaluation of Treatments to Improve Smoking Cessation Medication Adherence

Intralesional Steroids in the Treatment of Alopecia Areata

Lutronic PicoPlus Exploratory Clinical Trial

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

Melanoma Detection by Oblique-Incidence Optical Spectroscopy

Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain

To Test for Photo Allergy Reaction of Sunscreens

Human Comedogenicity Test

Vital Signs Patch Early Feasibility and Usability Study v1.0